Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 15/20 | 0.67 |
| ▸ | LATS1 | O95835 | 1/20 | 0.49 |
| ▸ | CCKAR | P32238 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | HTR6 | P50406 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formamide SCHEMBL28651025 | 0.93 | PTGDR2 (0.60) | PTGDR2LATS1CCKARCYP2C19HTR6 | |
| SCHEMBL15635129 | 0.86 | PTGDR2 (0.64) | PTGDR2LATS1CCKARCYP2C19HTR6 | |
| SCHEMBL4583577 | 0.86 | PTGDR2 (0.64) | PTGDR2LATS1CCKARCYP2C19HTR6 | |
| SCHEMBL20005127 | 0.86 | PTGDR2 (0.57) | PTGDR2LATS1CCKARCYP2C19HTR6 | |
| SCHEMBL17827487 | 0.82 | PTGDR2 (0.63) | PTGDR2LATS1CCKARCYP2C19HTR6 | |
| SCHEMBL1941139 | 0.80 | PTGDR2 (1.00) | PTGDR2CCKAR | |
| SCHEMBL1898444 | 0.79 | PTGDR2 (0.66) | PTGDR2LATS1CCKAR | |
| SCHEMBL2962255 | 0.78 | PTGDR2 (0.46) | PTGDR2LATS1CCKARHTR6 | |
| SCHEMBL4616627 | 0.78 | PTGDR2 (0.55) | PTGDR2LATS1CCKARCYP2C19HTR6 | |
| SCHEMBL13008027 | 0.77 | PTGDR2 (0.54) | PTGDR2LATS1CCKARCYP2C19HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338452-B2 | Raf inhibitor compounds and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-20110110889-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | Array Bio Pharma Inc. (US) | 2011-05-12 | — | — | US | disclosed |
| EP-2265608-A2 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2010-12-29 | — | — | EP | disclosed |
| WO-2009111278-A2 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2009-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110110889-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | PTGDR2 2694/4885LATS1 287/4885CCKAR 3598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.